Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 1

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
,517,143 and 9,857,143 shares issued and outstanding, excluding 23,000,000 and 0 shares subject to redemption as of September 30, 2025 and December 31, 2024, respectively 
     1,052  
     986 
  
    Share subscription
    receivable 
     (608,822) 
     — 
  
    Additional
    paid-in capital 
     —  
     34,014 
  
    Accumulated
    deficit 
     (6,720,645) 
     (279,845)
  
    Total
    Shareholders’ Deficit 
     (7,328,415) 
     (244,845)
  
    TOTAL
    LIABILITIES AND SHAREHOLDERS’ DEFICIT 
    $237,632,428  
    $550,824 

The
accompanying notes are an integral part of the unaudited financial statements.

1

DRUGS
MADE IN AMERICA ACQUISITION CORP.

STATEMENTS
OF OPERATIONS

(UNAUDITED) 

    Three Months Ended September 30, 2025  
    Nine Months Ended September 30, 2025  
    Three Months Ended September 30, 2024  
    For the Period from May 23, 2024 (inception) through September 30, 2024 
  
    General and administrative costs 
    $263,703  
    $726,547  
    $144,928  
    $199,859 
  
    Loss from operations 
     (263,703) 
     (726,547) 
     (144,928) 
     (199,859)

    OTHER INCOME 

    Interest earned on cash and investments held in Trust Account 
     2,448,266  
     6,454,232  
     —  
     — 
  
    Total other income 
     2,448,266  
     6,454,232  
     —  
     — 

    NET INCOME (LOSS) 
    $2,184,563  
    $5,727,685  
    $(144,928) 
    $(199,859)

    Weighted average redeemable ordinary shares outstanding – basic and diluted 
     23